Home › Small Cell Lung Cancer
Small Cell Lung Cancer clinical trials recruiting in the U.S.
100 studies for Small Cell Lung Cancer are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX26 studies
- New York City, NY23 studies
- Arlington, VA22 studies
- Boston, MA22 studies
- Los Angeles, CA20 studies
- Nashville, TN20 studies
- Orlando, FL14 studies
- Chicago, IL13 studies
- Cleveland, OH13 studies
- Dallas, TX13 studies
- St. Louis, MO13 studies
- Washington, DC13 studies
- Detroit, MI12 studies
- Seattle, WA12 studies
- Baltimore, MD11 studies
- San Antonio, TX11 studies
- Philadelphia, PA10 studies
- Edison, NJ10 studies
- Tampa, FL10 studies
- Miami, FL10 studies
- Grand Rapids, MI9 studies
- Atlanta, GA9 studies
- Queens, NY9 studies
- Omaha, NE8 studies
- Portland, OR8 studies
- Cedar Rapids, IA8 studies
- Indianapolis, IN8 studies
- Lexington, KY8 studies
- Akron, OH8 studies
- Durham, NC8 studies
- Aurora, CO8 studies
- Austin, TX7 studies
- Greenburgh, NY7 studies
- Cincinnati, OH7 studies
- Louisville, KY7 studies
- New Haven, CT7 studies
- Columbus, OH7 studies
- Irving, TX6 studies
- Ann Arbor, MI6 studies
- Denver, CO6 studies
By state
- Alabama10 studies
- Arizona10 studies
- Arkansas5 studies
- California35 studies
- Colorado16 studies
- Connecticut9 studies
- District of Columbia6 studies
- Florida39 studies
- Georgia12 studies
- Illinois23 studies
- Indiana11 studies
- Iowa8 studies
- Kansas3 studies
- Kentucky16 studies
- Maryland19 studies
- Massachusetts23 studies
- Michigan26 studies
- Minnesota10 studies
- Missouri18 studies
- Nebraska10 studies
- New Jersey17 studies
- New Mexico3 studies
- New York33 studies
- North Carolina15 studies
- Ohio26 studies
- Oklahoma5 studies
- Oregon9 studies
- Pennsylvania15 studies
- South Carolina7 studies
- South Dakota3 studies
- Tennessee24 studies
- Texas42 studies
- Utah9 studies
- Virginia29 studies
- Washington15 studies
- Wisconsin11 studies
Recently updated studies
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT06805825A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07488676A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT03460977A Study of Armored CAR T Cells in People With Cancer
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07783477BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07625644Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
RecruitingPhase 2
Ages 18 to 120 · All sexes · Updated Nov 12, 2026 · NCT06228066DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07707895A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06646276A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07843940DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07472517A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07099898A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Nov 10, 2026 · NCT06066138A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07459634A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Nov 5, 2026 · NCT06586957MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT05903092VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
RecruitingPhase 1/2
Ages 18 to 80 · All sexes · Updated Nov 4, 2026 · NCT03556228Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
RecruitingObservational study
Ages 21 to 90 · All sexes · Updated Nov 3, 2026 · NCT00900419A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07465757A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT0680763218F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
RecruitingPhase 2
Ages 18 to 120 · All sexes · Updated Oct 29, 2026 · NCT06503146Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Oct 29, 2026 · NCT07509034A Study of MGC026 in Participants With Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06242470A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT07155174PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT04199741SMARCA4/2 Inhibitor for POU2F3-Positive SCLC
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT07551635From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.